Anika Therapeutics Liabilities 2024

Anika Therapeutics Aktienanalyse

What does Anika Therapeutics do?

Anika Therapeutics Inc is a global biotechnology company specializing in the development and manufacturing of therapeutic products for orthopedic, ophthalmologic, and dermatologic treatment. It was founded in 1992 in Bedford, Massachusetts and has since maintained its headquarters there while expanding its operations worldwide. Business model Anika Therapeutics' business model is based on the development, manufacturing, and commercialization of innovative and cost-effective medical devices that use natural substances to enable rapid and powerful repair of the human body in various orthopedic, ophthalmologic, and dermatologic conditions. The company leverages its expertise in hyaluronan biology and technology to produce products based on this substance for the regeneration and healing of tissues such as cartilage, skin, and eyes. History Anika Therapeutics was founded by Charles Sherwood and Jeffrey Palmer to develop a synthetic hyaluronic acid product for the treatment of joint disorders. The first clinical study was conducted in 1996, and Anika received FDA approval for the product, marketed as Orthovisc, in 1999. Since then, Anika has expanded its presence in the industry through acquisitions, partnerships, and expansion into new geographical areas. Divisions Orthopedics In orthopedics, Anika Therapeutics offers a wide range of products for the treatment of joint disorders such as osteoarthritis and arthritis. These include Orthovisc, the company's original product, as well as Monovisc, a single-component viscosupplement that allows for easy injection into the joint, thus reducing the procedure and recovery time. Another product is Cingal, a combination product of hyaluronic acid and corticosteroid that provides effective pain relief. Ophthalmology Anika Therapeutics also manufactures products for ophthalmology. The company has a portfolio of products used for surgical procedures such as cataract surgery and vitrectomy (a surgery on the eye's vitreous body). These are available under the brand names Visian and Amvisc. Dermatology Anika Therapeutics is also active in dermatology, where it offers products for skin regeneration. This portfolio includes solutions such as Hyalofill, a hyaluronic acid-based filler substance used for restoring skin elasticity and treating wrinkles and scars. In summary, Anika Therapeutics is a global biotechnology company specializing in the development, manufacturing, and commercialization of therapeutic products in the field of orthopedics, ophthalmology, and dermatology. The company leverages its expertise in hyaluronan biology and technology to develop innovative and cost-effective medical devices that enable rapid and powerful repair of the human body in various conditions. Since its founding in 1992, the company has built a successful history of growth and expansion through acquisitions, partnerships, and expansion into new geographical areas. Anika Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Anika Therapeutics's Liabilities

Anika Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Anika Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Anika Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Anika Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Anika Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Anika Therapeutics Stock

What is the level of liabilities of Anika Therapeutics this year?

Anika Therapeutics has a debt balance of 58.37 M USD this year.

What were the liabilities of Anika Therapeutics compared to the previous year?

The liabilities of Anika Therapeutics have increased by -8.23% dropped compared to the previous year.

What are the consequences of high debt for investors of Anika Therapeutics?

High liabilities can pose a risk for investors of Anika Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Anika Therapeutics?

Low liabilities mean that Anika Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Anika Therapeutics affect the company?

An increase in liabilities of Anika Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Anika Therapeutics affect the company?

A decrease in the liabilities of Anika Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Anika Therapeutics?

Some factors that can influence the liabilities of Anika Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Anika Therapeutics so important for investors?

The liabilities of Anika Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Anika Therapeutics take to modify the liabilities?

To change its liabilities, Anika Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Anika Therapeutics pay?

Over the past 12 months, Anika Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Anika Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Anika Therapeutics?

The current dividend yield of Anika Therapeutics is .

When does Anika Therapeutics pay dividends?

Anika Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Anika Therapeutics?

Anika Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Anika Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Anika Therapeutics located?

Anika Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Anika Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Anika Therapeutics from 6/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/19/2024.

When did Anika Therapeutics pay the last dividend?

The last dividend was paid out on 6/19/2024.

What was the dividend of Anika Therapeutics in the year 2023?

In the year 2023, Anika Therapeutics distributed 0 USD as dividends.

In which currency does Anika Therapeutics pay out the dividend?

The dividends of Anika Therapeutics are distributed in USD.